CN1357037A - 生物活性材料的保存方法 - Google Patents
生物活性材料的保存方法 Download PDFInfo
- Publication number
- CN1357037A CN1357037A CN00809328A CN00809328A CN1357037A CN 1357037 A CN1357037 A CN 1357037A CN 00809328 A CN00809328 A CN 00809328A CN 00809328 A CN00809328 A CN 00809328A CN 1357037 A CN1357037 A CN 1357037A
- Authority
- CN
- China
- Prior art keywords
- active materials
- virus
- trehalose
- biological active
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 239000011149 active material Substances 0.000 title claims abstract description 55
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 55
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 55
- 229920001661 Chitosan Polymers 0.000 claims abstract description 49
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 46
- 229960005486 vaccine Drugs 0.000 claims abstract description 43
- 238000001035 drying Methods 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 239000011159 matrix material Substances 0.000 claims abstract description 27
- 241000700605 Viruses Species 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 4
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 16
- 231100000252 nontoxic Toxicity 0.000 claims description 15
- 230000003000 nontoxic effect Effects 0.000 claims description 15
- 241000204031 Mycoplasma Species 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 13
- 102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 claims description 10
- 101000907951 Homo sapiens Chymotrypsin-like elastase family member 3B Proteins 0.000 claims description 10
- 208000037933 contagious bovine pleuropneumonia Diseases 0.000 claims description 10
- 150000003625 trehaloses Chemical class 0.000 claims description 9
- 241000711897 Rinderpest morbillivirus Species 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 201000005404 rubella Diseases 0.000 claims description 5
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 241001428894 Small ruminant morbillivirus Species 0.000 claims description 4
- 241000710772 Yellow fever virus Species 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 201000006509 pleuropneumonia Diseases 0.000 claims description 4
- 229940051021 yellow-fever virus Drugs 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 201000005505 Measles Diseases 0.000 claims description 3
- 241000711386 Mumps virus Species 0.000 claims description 3
- 241000710799 Rubella virus Species 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 208000005647 Mumps Diseases 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 230000000630 rising effect Effects 0.000 claims description 2
- 241000712079 Measles morbillivirus Species 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 abstract description 22
- 239000000463 material Substances 0.000 abstract description 19
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 229940074410 trehalose Drugs 0.000 description 39
- 239000000047 product Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 8
- 230000018044 dehydration Effects 0.000 description 7
- 238000006297 dehydration reaction Methods 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 4
- 241000282552 Chlorocebus aethiops Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000002016 disaccharides Chemical class 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 208000006257 Rinderpest Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000010981 drying operation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940074409 trehalose dihydrate Drugs 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 2
- 208000000655 Distemper Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- VHOQXEIFYTTXJU-UHFFFAOYSA-N Isobutylene-isoprene copolymer Chemical group CC(C)=C.CC(=C)C=C VHOQXEIFYTTXJU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 241000142921 Tardigrada Species 0.000 description 2
- 102100038126 Tenascin Human genes 0.000 description 2
- 108010008125 Tenascin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000014058 canine distemper Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 241001672739 Artemia salina Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000231614 Macrobiotus hufelandi Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000202936 Mycoplasma mycoides Species 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 244000223072 Narcissus jonquilla Species 0.000 description 1
- 235000013862 Narcissus jonquilla Nutrition 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000711502 Paramyxovirinae Species 0.000 description 1
- 208000007634 Peste-des-Petits-Ruminants Diseases 0.000 description 1
- 241000710801 Rubivirus Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000195974 Selaginella Species 0.000 description 1
- 241000967223 Selaginella pilifera Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000004683 dihydrates Chemical group 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- -1 trehalose dihydrate compound Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (26)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9914412.3A GB9914412D0 (en) | 1999-06-22 | 1999-06-22 | Method for the preservation of viruses,bacteria and biomolecules |
GB9914412.3 | 1999-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1357037A true CN1357037A (zh) | 2002-07-03 |
CN1168819C CN1168819C (zh) | 2004-09-29 |
Family
ID=10855729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008093288A Expired - Fee Related CN1168819C (zh) | 1999-06-22 | 2000-06-21 | 生物活性材料的保存方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6841168B1 (zh) |
EP (1) | EP1187907B1 (zh) |
CN (1) | CN1168819C (zh) |
AT (1) | ATE276355T1 (zh) |
AU (1) | AU5413500A (zh) |
DE (1) | DE60013821T2 (zh) |
ES (1) | ES2228540T3 (zh) |
GB (1) | GB9914412D0 (zh) |
WO (1) | WO2000078924A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100375636C (zh) * | 2005-09-29 | 2008-03-19 | 中国农业大学 | 一种对微生态制剂有保护作用的糖类组合物的用途 |
CN103140145A (zh) * | 2010-08-13 | 2013-06-05 | 高级生物营养公司 | 用于生物材料的干的贮存稳定用组合物 |
CN105663171A (zh) * | 2009-01-09 | 2016-06-15 | 剑桥企业有限公司 | 用于口服递送的活细胞制剂 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7569342B2 (en) * | 1997-12-10 | 2009-08-04 | Sierra Molecular Corp. | Removal of molecular assay interferences |
US20080064108A1 (en) * | 1997-12-10 | 2008-03-13 | Tony Baker | Urine Preservation System |
US20040042972A1 (en) * | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
US20050118058A1 (en) * | 2003-12-01 | 2005-06-02 | Erning Xia | Gentle preservative compositions for self-preserving solutions |
CA2569276C (en) * | 2004-06-02 | 2018-01-23 | Victor Bronshtein | Preservation by vaporization |
GB0517688D0 (en) * | 2005-08-31 | 2005-10-05 | Cambridge Biostability Ltd | Improvements in the stabilisation of biological materials |
GB0523638D0 (en) | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
EP1991204A2 (en) * | 2006-02-24 | 2008-11-19 | Novartis AG | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
US8399230B2 (en) * | 2006-10-12 | 2013-03-19 | Kemin Industries, Inc. | Heat-stable enzyme compositions |
US20090081785A1 (en) * | 2007-09-24 | 2009-03-26 | Hememics Biotechnologies, Inc. | Desiccated Biologics And Methods Of Preparing The Same |
US20090090022A1 (en) * | 2007-10-09 | 2009-04-09 | Hememics Biotechnologies, Inc. | Desiccation Chamber and Methods for Drying Biological Materials |
JP5804453B2 (ja) * | 2009-05-14 | 2015-11-04 | 国立大学法人 東京大学 | 結晶性ポリオール微粒子及びその調製方法 |
WO2011103114A1 (en) | 2010-02-17 | 2011-08-25 | Hememics Biotechnologies, Inc. | Preservation solutions for biologics and methods related thereto |
GB201101950D0 (en) * | 2011-02-04 | 2011-03-23 | Anhydro Ltd | Vaccine compositions |
US20120222979A1 (en) | 2011-03-04 | 2012-09-06 | Elwha LLC, a limited liability company of the State of Delaware | Glassy compositions |
KR102276161B1 (ko) | 2011-10-25 | 2021-07-14 | 프로테나 바이오사이언시즈 리미티드 | 항체 제형 및 방법 |
US9938558B2 (en) | 2015-06-25 | 2018-04-10 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
AU2016282996A1 (en) | 2015-06-25 | 2018-01-18 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
US10851399B2 (en) | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
NZ743958A (en) | 2016-01-07 | 2023-07-28 | Native Microbials Inc | Methods for improving milk production by administration of microbial consortia |
CA3048246A1 (en) | 2016-12-28 | 2018-07-05 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon |
EP3562955A4 (en) | 2016-12-28 | 2020-08-12 | Ascus Biosciences, Inc. | METHODS, APPARATUS AND SYSTEMS FOR THE ANALYSIS OF STRAINS OF MICRO-ORGANISMS OF HETEROGENEOUS COMMUNITIES COMPLEX WITH TRACEOR ANALYZES, DETERMINATION OF THEIR INTERACTIONS AND FUNCTIONAL RELATIONSHIPS, AND SUMMARY OF MICROBIAL SETS OF MICROBIAL SETS AND MICROBIAL SETS INCLUDING MICROBIAL SETS AND INGREDIENTS |
CN110913702A (zh) | 2017-04-28 | 2020-03-24 | 埃斯库斯生物科技股份公司 | 利用微生物的人造生物集合在反刍动物中用于支持谷物加强剂和/或能量加强剂饮食的方法 |
EP4204539A1 (en) * | 2020-08-28 | 2023-07-05 | Chr. Hansen A/S | Microencapsulation of microbial culture using octenyl succinic anhydride starch-chitosan complex coacervate |
CN112471476A (zh) * | 2020-11-18 | 2021-03-12 | 山东丰香园食品股份有限公司 | 一种具有补脑及美白作用的芝麻粉及其制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ226170A (en) * | 1987-09-18 | 1990-07-26 | Ethicon Inc | Stable freeze-dried pharmaceutical composition containing epidermal growth factor |
GB8801338D0 (en) * | 1988-01-21 | 1988-02-17 | Quadrant Bioresources Ltd | Preservation of viruses |
GB9125695D0 (en) * | 1991-12-03 | 1992-01-29 | Mastavac Limited | Medical preparations |
FR2694895B1 (fr) * | 1992-08-20 | 1994-11-10 | Coletica | Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification. |
WO1995013799A1 (en) * | 1993-11-19 | 1995-05-26 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of biodegradable microparticles containing a biologically active agent |
US5972707A (en) * | 1994-06-27 | 1999-10-26 | The Johns Hopkins University | Gene delivery system |
ATE239451T1 (de) * | 1995-06-07 | 2003-05-15 | Elan Drug Delivery Ltd | Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen |
US5900238A (en) * | 1995-07-27 | 1999-05-04 | Immunex Corporation | Vaccine delivery system |
GB9522351D0 (en) * | 1995-11-01 | 1996-01-03 | Medeva Holdings Bv | Vaccine compositions |
GB9525083D0 (en) * | 1995-12-07 | 1996-02-07 | Danbiosyst Uk | Vaccine compositions |
DE69810755T2 (de) * | 1997-02-07 | 2003-08-07 | Elan Drug Delivery Ltd | Verfahren und zusammensetzungen zur herstellung getrockneter, lagerungsstabiler blutplättchen |
DE69735600T2 (de) * | 1997-11-26 | 2007-01-25 | Universal Preservation Technologies, Inc., San Diego | Konservierung empfindlicher biologischer proben durch verglasung |
-
1999
- 1999-06-22 GB GBGB9914412.3A patent/GB9914412D0/en not_active Ceased
-
2000
- 2000-06-21 AU AU54135/00A patent/AU5413500A/en not_active Abandoned
- 2000-06-21 ES ES00938911T patent/ES2228540T3/es not_active Expired - Lifetime
- 2000-06-21 EP EP00938911A patent/EP1187907B1/en not_active Expired - Lifetime
- 2000-06-21 US US10/018,834 patent/US6841168B1/en not_active Expired - Fee Related
- 2000-06-21 CN CNB008093288A patent/CN1168819C/zh not_active Expired - Fee Related
- 2000-06-21 WO PCT/GB2000/002254 patent/WO2000078924A1/en active IP Right Grant
- 2000-06-21 AT AT00938911T patent/ATE276355T1/de not_active IP Right Cessation
- 2000-06-21 DE DE60013821T patent/DE60013821T2/de not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100375636C (zh) * | 2005-09-29 | 2008-03-19 | 中国农业大学 | 一种对微生态制剂有保护作用的糖类组合物的用途 |
CN105663171A (zh) * | 2009-01-09 | 2016-06-15 | 剑桥企业有限公司 | 用于口服递送的活细胞制剂 |
CN105663171B (zh) * | 2009-01-09 | 2020-09-22 | 剑桥企业有限公司 | 用于口服递送的活细胞制剂 |
CN103140145A (zh) * | 2010-08-13 | 2013-06-05 | 高级生物营养公司 | 用于生物材料的干的贮存稳定用组合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2000078924A1 (en) | 2000-12-28 |
ES2228540T3 (es) | 2005-04-16 |
AU5413500A (en) | 2001-01-09 |
CN1168819C (zh) | 2004-09-29 |
DE60013821T2 (de) | 2005-11-17 |
US6841168B1 (en) | 2005-01-11 |
EP1187907B1 (en) | 2004-09-15 |
DE60013821D1 (de) | 2004-10-21 |
GB9914412D0 (en) | 1999-08-18 |
EP1187907A1 (en) | 2002-03-20 |
ATE276355T1 (de) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1168819C (zh) | 生物活性材料的保存方法 | |
CN1433465A (zh) | 保存病毒和支原体的方法 | |
Burke et al. | Formulation, stability, and delivery of live attenuated vaccines for human use | |
CN1258379C (zh) | 肉毒杆菌毒素药物组合物 | |
JP6896802B2 (ja) | 室温安定であるワクチンの乾燥製剤 | |
CN101146518B (zh) | 化学限定的稳定剂组合物的制备方法 | |
CN1053590C (zh) | 冻干甲型肝炎减毒活疫苗及其保护剂 | |
CN104998257A (zh) | 用于活的减毒病毒的方法和组合物 | |
CN1420721A (zh) | 通过干燥处理制备于环境温度贮存的含有需稳定化的敏感性生物制品的保存用混合物 | |
CN1683011A (zh) | 含蜂胶佐剂的人用疫苗及其制备方法 | |
CN101730544B (zh) | Pitman moore狂犬病病毒株对原代鸡胚成纤维细胞培养物的适应方法 | |
CN1887275A (zh) | 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法 | |
CN105999281A (zh) | 禽类活病毒用冻干保护剂、制备方法及应用 | |
CN1321694C (zh) | 冻干剂型艾滋病重组痘病毒安卡拉株载体疫苗及其制备方法 | |
CN105154377A (zh) | 重组鸡白痢沙门菌、制备方法及应用 | |
CN104248761B (zh) | 一种疫苗组合物及其制备方法和应用 | |
CN114652840A (zh) | 一种犬类病毒四联活疫苗的冻干保护剂及其制备方法和应用 | |
RU2378013C1 (ru) | Способ изготовления вирусвакцины против ньюкаслской болезни птиц для орального применения | |
BEHROUZIKHAH et al. | Evaluation on stability process of Brucella melitensis-Rev. 1 vaccine in Iran | |
RU2336090C2 (ru) | Способ доставки днк в макроорганизм для разработки вакцин и соматической генной терапии | |
CN1864744A (zh) | 含有尿酸氧化酶的药用制剂 | |
EA025263B1 (ru) | Разбавитель-адъювант для сухой живой вакцины против трихофитии крупного рогатого скота | |
CN1320421A (zh) | 噬菌蛭弧菌冻干制剂及其生产工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ANHAI DELUO CO., LTD. Free format text: FORMER OWNER: ERIC EDWARD WORRALL Effective date: 20021226 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20021226 Address after: British North Lincolnshire Applicant after: Anhaidro Co., Ltd. Address before: The British brand Applicant before: Eric Edward Worrall |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040929 Termination date: 20100621 |